Comprehensive Analysis of Grade 4 Tumors: Curative Trajectories, Molecular Pathogenesis, and Multidisciplinary Management of Glioblastoma

Background: Glioblastoma multiforme (GBM) is a universally lethal World Health 
Organization (WHO) grade 4 astrocytoma. This review analyzes the current paradigms in 
basic, applied, and clinical research to evaluate curative trajectories. 
Methods: A comprehensive, multi-disciplinary review integrating molecular 
pathogenesis, advanced neurosurgical innovations, emerging nanomedicine, artificial 
intelligence-driven prognostic modeling, and qualitative patient and caregiver 
perspectives. 
Results: Molecular profiling, including isocitrate dehydrogenase (IDH) status and 
epigenetic markers, has revolutionized the understanding of GBM heterogeneity. 
Next-generation modalities, such as dendritic cell vaccines (e.g., DCVax-L), oncolytic 
viruses, and Tumor Treating Fields, are generating unprecedented long-term survival 
extensions. Concurrently, nanomedicine and fluorescence-guided surgery are optimizing 
targeted drug delivery and surgical resection margins. However, profound socioeconomic 
and ethical disparities restrict global access to these therapeutics. 
Conclusions: Eradicating GBM requires a convergence of precision oncology, advanced 
bioengineering, early palliative integration, and systemic healthcare reforms to ensure 
equitable access and preserve patient dignity.